NextCure Reports Q3 2026 Net Loss of $6.8 Million as Merger Financing Reaches $820 Million

NextCure reported a third-quarter 2026 net loss of $6.8 million, compared with a loss of $8.6 million a year earlier. Cash, cash equivalents and marketable securities totaled $8.7 million at September 30, 2026. The company also reported progress toward its proposed merger with Avere Therapeutics, b…